Navigation Links
MolecularHealth demonstrates Personalized Cancer Therapy Solutions at 2013 CeBIT
Date:3/5/2013

NEW YORK and HEIDELBERG, Germany, March 5, 2013 /PRNewswire/ --  MolecularHealth, a leader in clinico-molecular informatics™, today announced that the company will demonstrate their latest capabilities at CeBIT 2013, taking place in Hannover, Germany March 5-9. The company is advancing precision medicine by providing decision support solutions that translate patient-specific molecular and genomic data, treatment-relevant clinical history, and published scientific evidence in combination with mechanism-based therapy knowledge into safer, more effective drug choices. MolecularHealth's Personalized Cancer Therapy Solutions offer health providers and patients an integrated service that unlocks evidence-based treatment strategies from the genome, patient clinical history and extensive knowledge about drug therapy mechanisms of action.

(Logo: http://photos.prnewswire.com/prnh/20130305/DA68911LOGO)

Benefitting from the unprecedented speed and performance of the SAP HANA® platform, the offering aims to tackle the challenges of immense bodies of disparate medical, biological and drug data, manual and time consuming analysis, and the increasingly complex treatment paradigms affecting pathologists, oncologists and patients and their families. MolecularHealth will demonstrate its Molecular Analysis of Side Effects™ (MASE) and Oncology Decision Support capabilities in the SAP booth, Hall 4 Stand C04. These capabilities reflect SAP's recent entry with the SAP HANA platform and partners such as MolecularHealth into the increasingly accessible field of genomics and next generation sequencing-driven clinical decision support.

About MolecularHealth

MolecularHealth, a clinico-molecular informatics company offering mechanism-based drug safety and Personalized Cancer Therapy Solutions, is advancing precision medicine by translating patient-specific molecular and genomic data, clinical history, drug knowledge and published scientific and medical evidence into safer, more effective drug choices for patients. The company's solutions range from a next generation drug safety assessment and prediction tool that analyzes the molecular basis of adverse events to a treatment decision support offering that informs evidence-based treatment strategies for cancer patients.  MolecularHealth's collaborators include the University of Texas MD Anderson Cancer Center, SAP AG, and the U.S. Food and Drug Administration (FDA). Visit www.molecularhealth.com.

© 2013 The MolecularHealth name and logo are trademarks of Molecular Health AG.

SAP, SAP HANA, and all SAP logos are trademarks or registered trademarks of SAP AG in Germany and in several other countries.
All other product and service names mentioned are the trademarks of their respective companies.


'/>"/>
SOURCE MolecularHealth
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
4. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
5. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
6. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
7. At SIIM 2012 Siemens Healthcare Demonstrates Departmental IT Solutions That Help Administrators Increase Access while Managing Costs
8. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
9. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
10. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
11. LIVE VIA SATELLITE: Physician Demonstrates New Medical Technology to Combat Back Pain without Major Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):